Marc R. Radke

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma”.

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Cancer Research(2021)10.1158/0008-5472.can-21-0774

N/A

2.1DataRank · unranked

90 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(22)00739-2

N/A

2.0DataRank · unranked

102 citations

Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders +16 more

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

NAR Cancer(2021)10.1093/narcan/zcab028

N/A

1.1DataRank · unranked

37 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +28 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056

N/A

0.813DataRank · unranked

225 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872

N/A

0.790DataRank · unranked

25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0.601DataRank · unranked

54 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1001

N/A

0.587DataRank · unranked

49 citations

Eve T. Rodler, William E. Barlow, Julie R. Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders +15 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0.571DataRank · unranked

44 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.07.690

N/A

0.358DataRank · unranked

5 citations

Emma Hazard, Elena Latorre‐Esteves, Brendan Kohrn, Talayeh Ghezelayagh, Jeanne Uy Fredrickson +9 more

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

medRxiv(2023)10.1101/2023.03.20.23287465

N/A

0.345DataRank · unranked

9 citations

John J. Krais, Cassandra J. Vandenberg, Yifan Wang, Pooja Patel, Kathy Q. Cai +30 more

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.10.419176

N/A

0.165DataRank · unranked

2 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +26 more

Characterization of a RAD51C -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.25.419978

N/A

0.165DataRank · unranked

2 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +25 more

Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.732

N/A

0.104DataRank · unranked

1 citations

David B. Zhen, Marc R. Radke, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong +5 more

Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions

Nature Communications(2025)10.1038/s41467-025-61283-2

N/A

0DataRank · unranked

7 citations

Yashpal Rawal, Anna L Palovcak-Lightbourn, Gayatri S. Ganesan, Phoebe S. Parker, Reagan A Russell +15 more

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.12.007

N/A

0DataRank · unranked

40 citations

Kathryn P. Pennington, Barbara M. Norquist, Nithisha Khasnavis, Marc R. Radke, Mark Kilgore +7 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.19.456799

N/A

0DataRank · unranked

0 citations

Kalyan Banda, Pooja Kumar, Robert F. Straub, Lacey E. Dobrolecki, Isabel V. Rodriguez +10 more

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer

Cancer Research Communications(2022)10.1158/2767-9764.crc-22-0314

N/A

0DataRank · unranked

11 citations

Brendan Kohrn, Jeanne Fredrickson, Enna Manhardt, Marc R. Radke, Ronit Katz +13 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

medRxiv(2022)10.1101/2022.12.02.22283037

N/A

0DataRank · unranked

2 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays

JCO Precision Oncology(2023)10.1200/po.22.00720

N/A

0DataRank · unranked

6 citations

Nithisha Khasnavis, Marc R. Radke, Kalyan Banda, Helen Davies, Christopher C. Pennil +10 more

Data from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

(2023)10.1158/0008-5472.c.6513498.v1

N/A

0DataRank · unranked

0 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more